These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

238 related articles for article (PubMed ID: 23281926)

  • 1. B-cell activating factor targeted therapy and lupus.
    Boneparth A; Davidson A
    Arthritis Res Ther; 2012; 14 Suppl 4(Suppl 4):S2. PubMed ID: 23281926
    [TBL] [Abstract][Full Text] [Related]  

  • 2. BAFF inhibition in SLE-Is tolerance restored?
    Jackson SW; Davidson A
    Immunol Rev; 2019 Nov; 292(1):102-119. PubMed ID: 31562657
    [TBL] [Abstract][Full Text] [Related]  

  • 3. BAFF and innate immunity: new therapeutic targets for systemic lupus erythematosus.
    Vincent FB; Morand EF; Mackay F
    Immunol Cell Biol; 2012 Mar; 90(3):293-303. PubMed ID: 22231653
    [TBL] [Abstract][Full Text] [Related]  

  • 4. B-Cell Maturation Antigen (BCMA) as a Biomarker and Potential Treatment Target in Systemic Lupus Erythematosus.
    Martin J; Cheng Q; Laurent SA; Thaler FS; Beenken AE; Meinl E; Krönke G; Hiepe F; Alexander T
    Int J Mol Sci; 2024 Oct; 25(19):. PubMed ID: 39409173
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeting BAFF and APRIL in systemic lupus erythematosus and other antibody-associated diseases.
    Samy E; Wax S; Huard B; Hess H; Schneider P
    Int Rev Immunol; 2017 Jan; 36(1):3-19. PubMed ID: 28215100
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Renal tubular epithelial cell-derived BAFF expression mediates kidney damage and correlates with activity of proliferative lupus nephritis in mouse and men.
    Schwarting A; Relle M; Meineck M; Föhr B; Triantafyllias K; Weinmann A; Roth W; Weinmann-Menke J
    Lupus; 2018 Feb; 27(2):243-256. PubMed ID: 28659046
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Belimumab therapy in systemic lupus erythematosus.
    Zouali M; Uy EA
    BioDrugs; 2013 Jun; 27(3):225-35. PubMed ID: 23568179
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The rationale for BAFF inhibition in systemic lupus erythematosus.
    Davidson A
    Curr Rheumatol Rep; 2012 Aug; 14(4):295-302. PubMed ID: 22535567
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Deleting the BAFF receptor TACI protects against systemic lupus erythematosus without extensive reduction of B cell numbers.
    Figgett WA; Deliyanti D; Fairfax KA; Quah PS; Wilkinson-Berka JL; Mackay F
    J Autoimmun; 2015 Jul; 61():9-16. PubMed ID: 26027434
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Belimumab for the treatment of systemic lupus erythematosus.
    Jordan N; D'Cruz DP
    Expert Rev Clin Immunol; 2015 Feb; 11(2):195-204. PubMed ID: 25543845
    [TBL] [Abstract][Full Text] [Related]  

  • 11. B cells targeting therapy in the management of systemic lupus erythematosus.
    Lee WS; Amengual O
    Immunol Med; 2020 Mar; 43(1):16-35. PubMed ID: 32107989
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Belimumab, a BLyS-specific inhibitor for the treatment of systemic lupus erythematosus.
    Espinosa G; Cervera R
    Drugs Today (Barc); 2010 Dec; 46(12):891-9. PubMed ID: 21589946
    [TBL] [Abstract][Full Text] [Related]  

  • 13. BAFF-neutralizing interaction of belimumab related to its therapeutic efficacy for treating systemic lupus erythematosus.
    Shin W; Lee HT; Lim H; Lee SH; Son JY; Lee JU; Yoo KY; Ryu SE; Rhie J; Lee JY; Heo YS
    Nat Commun; 2018 Mar; 9(1):1200. PubMed ID: 29572471
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeting the BLyS-APRIL signaling pathway in SLE.
    La Cava A
    Clin Immunol; 2013 Sep; 148(3):322-7. PubMed ID: 23269199
    [TBL] [Abstract][Full Text] [Related]  

  • 15. B-Cell Activating Factor as a Cancer Biomarker and Its Implications in Cancer-Related Cachexia.
    Rihacek M; Bienertova-Vasku J; Valik D; Sterba J; Pilatova K; Zdrazilova-Dubska L
    Biomed Res Int; 2015; 2015():792187. PubMed ID: 26339644
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Spotlight on blisibimod and its potential in the treatment of systemic lupus erythematosus: evidence to date.
    Lenert A; Niewold TB; Lenert P
    Drug Des Devel Ther; 2017; 11():747-757. PubMed ID: 28331294
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of BAFF Neutralization on Atherosclerosis Associated With Systemic Lupus Erythematosus.
    Saidoune F; Even G; Lamri Y; Chezel J; Gaston AT; Escoubet B; Papo T; Charles N; Nicoletti A; Sacre K
    Arthritis Rheumatol; 2021 Feb; 73(2):255-264. PubMed ID: 32783382
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Belimumab alters transitional B-cell subset proportions in patients with stable systemic lupus erythematosus.
    Benitez A; Torralba K; Ngo M; Salto LM; Choi KS; De Vera ME; Payne KJ
    Lupus; 2019 Oct; 28(11):1337-1343. PubMed ID: 31423896
    [TBL] [Abstract][Full Text] [Related]  

  • 19. BAFF-R and TACI expression on CD3+ T cells: Interplay among BAFF, APRIL and T helper cytokines profile in systemic lupus erythematosus.
    Salazar-Camarena DC; Ortíz-Lazareno P; Marín-Rosales M; Cruz A; Muñoz-Valle F; Tapia-Llanos R; Orozco-Barocio G; Machado-Contreras R; Palafox-Sánchez CA
    Cytokine; 2019 Feb; 114():115-127. PubMed ID: 30467093
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The BAFF/APRIL system in SLE pathogenesis.
    Vincent FB; Morand EF; Schneider P; Mackay F
    Nat Rev Rheumatol; 2014 Jun; 10(6):365-73. PubMed ID: 24614588
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.